BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 601–700 of 894
Pacholczak‐Madej, R., Kosałka-Węgiel, J., Kuszmiersz, P., Mituś, J. W., Püsküllüoğlu, M., Grela-Wojewoda, A., Korkosz, M., & Bazan‐Socha, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064926 · Cited by 13
“BTLA-deficient T cells have increased responses to antigen stimulation in vitro [19].”
BackgroundZhao, N., Zhang, Z., Wang, Q., Li, L., Wei, Z., Chen, H., Zhou, M., Liu, Z., & Su, J. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104801 · Cited by 10
“38,39 Accordingly, BTLA can likely substitute for PD-1 when PD-1 is blocked.”
B- and T-Lymphocyte Attenuator Expression on Regulatory T-Cells in Patients with Severe Sepsis
Liu, Q., Lu, Y., An, L. T., & Li, C. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.244104 · Cited by 10
Wang, W., Yang, X., Guo, M., Pan, Z., Shang, M., Qiu, M.-J., Wu, J., Jia, J., Ying-liang, L., Wen-ting, Z., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.03.007 · Cited by 12
Role of T cell co‐stimulation in murine models of allergic asthma
Deurloo, D. T., & van Oosterhout, A. J. M. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.01847.x · Cited by 10
(2015) · Europe PMC (PubMed Central) · Cited by 10
Robson, M. I., Heras, J. I. D. L., Czapiewski, R., Sivakumar, A., Kerr, A. R. W., & Schirmer, E. C. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/062224 · Cited by 10
Park, H.-S., Sung, W. J., Park, Y.-Y., Hong, J., Oh, H. K., & Lee, H. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.116753 · Cited by 9
“Importantly, the persistence of Th2/Th17 cells in chronic AD lesions is associated with resistance to AICD, a regulatory mechanism that normally limits effector T cell survival after antigen stimulation [14].”
Rs1982809 is a functional biomarker for the prognosis of severe post-traumatic sepsis and MODs
Gan, L., Hu, C., Deng, Z., Lu, H., Sun, J., Peng, G., Jiang, J., Zeng, L., & Deng, J. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219880490 · Cited by 12
A pan-cancer analysis of the biological function and clinical value of BTLA in tumors
Jiang, X., He, J., WANG, Y., LIU, J., LI, X., HE, X., & Cai, H. (2022) · Biocell · doi:10.32604/biocell.2023.025157 · Cited by 10
“Together with CTLA-4 and PD-1, BTLA is a key player in regulating T cell function (Watanabe et al., 2003), and it is a part of the inhibitory receptors expressed on lymphocytes.”
BackgroundSong, Y., Ma, J., Zhang, H., Xie, Y., Peng, Z., Shuang, Y.-R., Li, F., Li, Y., Yang, H., Zou, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59461-3 · Cited by 9
“B and T lymphocyte attenuator (BTLA), a member of the CD28 receptor family, is expressed on T and B lymphocytes and dendritic cells (DCs) 3 .”
BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation
Gertner-Dardenne, J., Fauriat, C., & Olive, D. (2013) · OncoImmunology · doi:10.4161/onci.25853 · Cited by 9
“B and T lymphocyte attenuator (BTLA), a recently described member of the CD28 family structurally related to cytotoxic T lymphocyte-associated protein 4 (CTLA4) and PD-1, is expressed by most lymphocytes.(2) BTLA binds herpes virus entry mediator A (HVEM), a member of the tumor necrosis factor (TNF) TNF receptor super…”
BackgroundT-cell Inhibitors: A Bench-to-Bedside Review
Das, S., Ariizumi, K., & Cruz, P. D. (2012) · Dermatitis · doi:10.1097/der.0b013e31826e43ed · Cited by 9
Xi, J., Wang, L., Yan, C., Song, J., Song, Y., Chen, J., Zhu, Y., Chen, Z., Jin, C., Ding, J., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.01 · Cited by 9
“It was demonstrated that BTLA-deficient mice have enhanced specific antibody reactions and improved sensitivity to EAE, with earlier disease onset, prolonged disease duration and increased clinical score (29).”
BackgroundJang, B., Park, Y.-K., Choi, I., Kim, S.-P., Hwang, J., Baek, W., Suh, M., Mun, K.-C., & Suh, S.-I. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1439 · Cited by 9
The influence of cyclosporin A on lymphocyte attenuator expression
Zeng, C., Yu, Z., Shu, S.-A., Wu, T., Yi, H., Lian, Z., & Zhao, Y. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.03.002 · Cited by 9
Strutt, T. M., Uzonna, J. E., McKinstry, K. K., & Bretscher, P. A. (2006) · International Immunology · doi:10.1093/intimm/dxl009 · Cited by 10
“However, it remains unclear which accessory or costimulatory molecules are essential for the generation of T cell responses because a number perform redundant roles, act in concert, or function in a temporal fashion (Boussiotis, Freeman, Gribben, & Nadler, 1996; Coyle & Gutierrez-Ramos, 2001; Croft & Dubey, 1997; Lani…”
BackgroundCommentary: Regulated equilibrium between opposite signals: a general paradigm for T cell function?
Moretta, A., & Bottino, C. (2004) · European Journal of Immunology · doi:10.1002/eji.200425388 · Cited by 9
High dimensional proteomic mapping of bone marrow immune characteristics in immune thrombocytopenia
Liu, F., Qu, Q., Lei, Y., Chen, Q., Chen, Y.-X., Li, M., Sun, X., Wu, Y., Huang, Q.-S., Fu, H., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2520-4 · Cited by 10
“There is evidence that BTLA negatively modulates the immune response, and mice with BTLA deletion have an increased susceptibility to autoimmune diseases (Oya et al., 2011; Watanabe et al., 2003; Wojciechowicz et al., 2022).”
Cheng, Y., Wang, J., Yu, Y., Wang, Q., Yang, R., Xia, B., Li, C., Lv, D., Yi, T., Han, L., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0022 · Cited by 9
Harnessing the immunotherapeutic potential of T-lymphocyte co-signaling molecules in transplantation
Ansari, A. W., Khan, M. A., Schmidt, R. E., & Broering, D. C. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.01.008 · Cited by 8
Dornieden, T., Wilde, B., Korth, J., Werner, K., Horn, P. A., Witzke, O., & Lindemann, M. (2019) · Journal of Immunology Research · doi:10.1155/2019/3926175 · Cited by 8
Han, S., Oh, J. S., & Kim, J. S. (2020) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01537-9 · Cited by 8
Karabon, L., Andrzejczak, A., Ciszak, L., Tomkiewicz, A., Szteblich, A., Bojarska-Junak, A. A., Roliński, J., Wołowiec, D., Wróbel, T., & Kosmaczewska, A. (2021) · Cells · doi:10.3390/cells10113009 · Cited by 9
Chen, Y., Hu, Z., Wang, Q., Ge, Y., Bai, L.-X., Wang, X., & Zhang, X. (2010) · Hybridoma · doi:10.1089/hyb.2009.0091 · Cited by 8
“They play critical roles in down-regulating T cell activation and proliferation at different stages of immune reaction.((3,4)) Mounting experimental evidence indicates that PD-1 is an important co-inhibitory molecule in down-regulating and terminating T cell immune responses.”
Year in review 2013: Critical Care – sepsis
de Montmollin, É., & Annane, D. (2014) · Critical Care · doi:10.1186/s13054-014-0578-x · Cited by 8
“T-cell and B-cell function [4].”
B7-H4’s Role “Beyond the Tumor”
Yu, N., Li, X., Zheng, S., & Li, X.-P. (2013) · Inflammation · doi:10.1007/s10753-013-9624-0 · Cited by 8
Youssef, R. M., El-Ramly, A. Z., Hussien, M. F., Shoukry, N. M., & Amr, K. S. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.12965 · Cited by 8
Ishida, W., Fukuda, K., Kajisako, M., Sumi, T., Matsuda, H., Yagita∥, H., & Fukushima, A. (2011) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-011-1695-8 · Cited by 8
“Although BTLA was originally identified as a murine Th1-specific gene owing to the finding that BTLA mRNA expression in Th1 cells was much higher than in Th2 cells by Northern blot analysis [20], it was also reported that BTLA is equally expressed on Th1 and Th2 cells, and its expression is lost in Th1/Th2 clones [29].”
Olive, D. (2006) · médecine/sciences · doi:10.1051/medsci/200622121069 · Cited by 9
BTLA agonist attenuates Th17-driven inflammation in a mouse model of steroid-resistant asthma
Quach, C., Li, X., Shafiei-Jahani, P., Li, M., Shen, S. M.-C., Helou, D. G., Hurrell, B. P., Soroosh, P., & Akbari, O. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552394 · Cited by 7
PDGFR kinase inhibitor protects against septic death via regulation of BTLA
Wang, Q., Deng, J., Sun, J., Zhang, H., Liu, D., Gao, C., Qiu, J., Liu, W., Qu, G., Wen, D., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2136-y · Cited by 7
“liferation and differentiation of lymphocytes (Douna et al., 2019; Watanabe et al., 2003).”
BackgroundGenome-wide mapping of the binding sites of myocyte enhancer factor 2A in chicken primary myoblasts
Wang, X., Zhang, J., Su, J., Huang, T., Lian, L., Nie, Q., Zhang, X., Li, J., & Wang, Y. (2024) · Poultry Science · doi:10.1016/j.psj.2024.104097 · Cited by 9
“Among the genes highly expressed in the immune system, B and T lymphocyte associated ( BTLA ) can signi fi - cantly inhibit T cell activation and proliferation (Watanabe et al., 2003).”
BackgroundInborn errors of immunity associated with defects of self‐tolerance checkpoints: The CD28 family
Rush‐Kittle, J., Gámez-Díaz, L. Y., & Grimbacher, B. (2022) · Pediatric Allergy and Immunology · doi:10.1111/pai.13886 · Cited by 7
Cui, Z., Liang, Z., Song, B., Zhu, Y., Chen, G., Gu, Y., Liang, B., Ma, J., & Song, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1180732 · Cited by 7
“Our results showed that checkpoints ’ expression is relatively high in the LR group, such as B-and T-lymphocyte attenuator (BTLA), Cytotoxic T lymphocyte associate protein-4 (CTLA4), and programmed cell death protein 1(PD-1).”
BackgroundPeptides targeting the BTLA-HVEM complex can modulate T cell immune response
Wojciechowicz, K., Kuncewicz, K., Lisowska, K. A., Wardowska, A., & Spodzieja, M. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106677 · Cited by 7
New Approaches to the Prevention of Organ Allograft Rejection and Tolerance Induction
Bagley, J., Tian, C., & Iacomini, J. (2007) · Transplantation · doi:10.1097/01.tp.0000269185.28701.45 · Cited by 7
“BTLA is a recently identified costimulatory receptor that is induced by activated CD4 and CD8 T cells and also expressed by B cells, macrophages, and bone marrow-derived myeloid dendritic cells (DC) (18).”
BackgroundGenome-Wide Profiling of In Vivo LPS-Responsive Genes in Splenic Myeloid Cells
Lee, M. S., Kim, B., Lee, S.-M., Cho, W.-C., Lee, W., Kang, J.-S., Choi, U. Y., Lyu, J., & Kim, Y.-J. (2013) · Molecules and Cells · doi:10.1007/s10059-013-2349-y · Cited by 8
“…the formation of T helper memory cells (Shinoda et al., 2012); Btla (B and T lymphocyte-associated), a known inhibitory receptor on T lymphocytes (Watanabe et al., 2003); Slfn4 (Schlafen-4), a potential modulator of myelopoiesis (van Zuylen et al., 2011); and Ibrdc3 (IBR domain-containing…”
BackgroundThe selective impact of transgenically expressed glucocorticoid receptor on T cells
Yakimchuk, K., Chen, L., Hasni, M. S., Okret, S., & Jondal, M. (2014) · Autoimmunity · doi:10.3109/08916934.2014.959164 · Cited by 7
“The analysis of CD4+ and CD8+ splenocytes has shown that the T cell population in mice was shifted toward a regulatory phenotype with increased percentages of Foxp3, CD25, GITR, CD39, BTLA and PD1 and CD122, CD39 in CD4+ cells from lck-GR mice (Figure 1B and supplementary Figure 4).”
InfluentialWang, Z., Wang, K., Yang, H., Han, Z., Tao, J., Chen, H., Ge, Y., Guo, M., Suo, C., Wei, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21941 · Cited by 7
“BTLA is up-regulated on activated T cells, but when conjugated with HVEM, a co-inhibitory signal suppresses T cell activation and differentiation in vitro [12].”
BackgroundHe, L., Xiao, J., Song, L., Zhou, R., Rong, Z., He, W., & Dai, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689269 · Cited by 7
“B and T lymphocyte attenuator (BTLA) is an inhibitory receptor of the Ig superfamily that plays an important role in negative immune regulation (17).”
BackgroundPD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
Isobe, K., Kakimoto, A., Mikami, T., Kaburaki, K., Kobayashi, H., Yoshizawa, T., Nakano, Y., Makino, T., Otsuka, H., Sano, G., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6442 · Cited by 9
“Programmed death 1 (PD-1) is a co-inhibitory receptor expressed on activated T and B cells and is involved in tumor immune escape (19-21).”
Transplant tolerance through costimulation blockade - are we there yet?
Vadivel, N. (2007) · Frontiers in bioscience · doi:10.2741/2283 · Cited by 7
The Many Sounds of T Lymphocyte Silence
Melero, I., Arina, A., & Chen, L. (2005) · Immunologic Research · doi:10.1385/ir:33:2:135 · Cited by 7
“To add more complexity to the co-stimulatory/co-inhibitory network, another inhibitory receptor BTLA has been identified that belongs to the CD28/CTLA-4 family ( 101 ).”
BackgroundInfluentialPD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
Kondo, R., Kondo, K., Nabeshima, K., Nishikimi, A., Ishida, Y., Shigeoka, T., & Dijkstra, J. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573492 · Cited by 8
Targeting B and T lymphocyte attenuator in cancer immunotherapy
Mortezaee, K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144953 · Cited by 7
Diefenhardt, P., Braumann, M., Schömig, T., Trinsch, B., Gonzalez, C. S., Becker-Gotot, J., Völker, L. A., Ester, L., Mandel, A. M., Hawiger, D., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000159 · Cited by 8
Aubergeon, L., Felten, R., Gottenberg, J., Dumortier, H., & Monneaux, F. (2024) · Cells · doi:10.3390/cells13242063 · Cited by 7
“Concerning BTLA signaling, its inhibitory function was demonstrated by in vitro hyperproliferative responses of BTLA-deficient B and T cells to specific BCR and TCR (B and T Cell Receptor) stimulation [3].”
Nishizaki, D., Choi, S. H., Pandya, C., Lee, S., Pabla, S., DePietro, P., Jensen, T. J., Kurzrock, R., & Kato, S. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00304 · Cited by 7
Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1
May, J. F., Kelly, R. G., Suen, A. Y. W., Kim, J. I., Kim, J., Anderson, C. C., Rayat, G. R., & Baldwin, T. A. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200775 · Cited by 7
Tahara, M., Kondo, Y., Yokosawa, M., Tsuboi, H., Takahashi, S., Shibayama, S., Matsumoto, I., & Sumida, T. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12455 · Cited by 6
Tian, C., Liu, Y., Yan, J., Liu, S.-D., Zhao, S., & Wang, H. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.10.019 · Cited by 6
Posttranslational Modifications and Death Receptor Signalling
Micheau, O. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56805-8_11 · Cited by 6
Co-inhibitory receptors, transcription factors and tolerance
Mohammadzadeh, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106572 · Cited by 6
T Cell Activation and Function: Role of Signal Strength
Ahmed, A., & Nandi, D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0_4 · Cited by 6
B7 Family Proteins in Cancer Progression: Immunological and Non-Immunological Functions
Ye, Q., Liu, J., & Xie, K. (2019) · Journal of Cancer Treatment and Diagnosis · doi:10.29245/2578-2967/2019/4.1171 · Cited by 6
LIGHT-related molecular network in the regulation of innate and adaptive immunity
Xu, Y., Tamada, K., & Chen, L. (2007) · Immunologic Research · doi:10.1007/bf02686093 · Cited by 6
“BTLA-deficient B cells showed slightly better responses to stimulation by anti-IgM ( 37 ).”
BackgroundInfluentialZhang, B., Zhao, X., Cao, J., Liu, Z., Wang, X., Li, R., Bo, H., Xu, K., & Guo, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1671482 · Cited by 9
“CD8 + T cells also expressed PDCD1 and LAG3 , indicating an exhaustion signature (53) (Supplementary Figure S7D).”
BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy
Chang, M., Lee, W.-C., Tai, Y., & Chiang, Y. (2025) · Pharmaceuticals · doi:10.3390/ph18121784 · Cited by 6
“Despite increasing recognition of its role in the tumor microenvironment (TME), the BTLA–HVEM axis remains comparatively underexplored [5,6].”
InfluentialChen, Y., Wang, X., Shen, Y., Zhang, H., Yu, C., Cheng, L., & Ge, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.004 · Cited by 5
Hussain, T., Saha, D., & Chakraborty, A. (2025) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.7.113 · Cited by 5
Mkhikian, H., Zhou, R. W., Saryan, H., Sánchez, C. D., Balakrishnan, A., Dang, J., Mortales, C., & Demetriou, M. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300568 · Cited by 6
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Lambert, L. J., Romero, C., Sheffler, D. J., Celeridad, M., Cosford, N. D. P., & Tautz, L. (2020) · Journal of Visualized Experiments · doi:10.3791/61457 · Cited by 7
Allosteric regulation of binding specificity of HVEM for CD160 and BTLA ligands upon G89F mutation
Shrestha, R., Garrett-Thomson, S. C., Liu, W., Almo, S. C., & Fiser, A. (2021) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2021.11.001 · Cited by 6
“For its part, the HVEM:BTLA complex initiates an inhibitory signal by inducing phosphorylation of the intracellular immunotyrosine inhibitory motif (ITIM) that recruits tyrosine phosphatases SHP1 and SHP2 (Sedy et al., 2005; Gavrieli et al., 2003; Watanabe et al., 2003).”
BackgroundYu, X., Zheng, Y., Zeng, D., Zhou, Y., Sun, J., Su, M., Zhang, H., Zheng, M., Huang, Z., Lin, W., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28129 · Cited by 7
“Previous studies have shown that CD8+CD57+ T cells express high programmed cell death‐1 (PD‐1) and exhibit enhanced cytotoxic potency and impaired proliferative capability.6 In this study, CD3+CD4−CD7+CD57− T cells expressed high levels of BTLA, a coinhibitory molecule similar to PD‐1.23 Therefore, consistent with the…”
ResultInfluentialCell-surface Milieu Remodeling in Human Dendritic Cell Activation
Udeshi, N. D., Xu, C., Jiang, Z., Gao, S. M., Yin, Q., Luo, W., Carr, S. A., Davis, M. M., & Li, J. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400089 · Cited by 5
“4B) (35, 36)—went down (Fig.”
Doladé, N. G., Rayego‐Mateos, S., García-Carrasco, A., Guérin, M., Martín-Ventura, J. L., Ruiz‐Ortega, M., Tharaux, P., & Valdivielso, J. M. (2023) · Clinical Science · doi:10.1042/cs20230399 · Cited by 5
Wang, X., Zhu, G., Huang, Z., Cao, L., Chen, Y., Wang, Q., & Zhang, X. (2012) · Hybridoma · doi:10.1089/hyb.2012.0052 · Cited by 5
“13) BTLA is the most recently represented member of the immunoglobulin superfamily of co-inhibitory receptors (14) ; it shares an unexpected ligand with LIGHT, LT-a , and HSV1 gD, HVEM, which belongs to the TNFR superfamily.”
Experimental advances in understanding allergic airway inflammation
Deppong, C. M., & Green, J. M. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s364 · Cited by 5
“BTLA can be found on B and T lymphocytes, macrophages, dendritic cells, and NK cells (96-97).”
BackgroundInfluentialT-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect
Wu, Y., Anasetti, C., & Yu, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00011-6 · Cited by 6
Pourmir, I., Gazeau, B., Basile, H. D. S., & Fabre, E. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.14 · Cited by 5
“Alternative IC Anti-PD-1/PD-L1 NSCLC Multiparametric FACS detecting alternative IC on CD8 TILs at baseline/after ICI Co-expression of alternative IC is associated with primary and secondary resistance [61,62]”
BackgroundLipińska, M., Ciura, P., Gumpelmair, S., Sikorska, E., Kuncewicz, K., Sieradzan, A. K., Steinberger, P., Wardowska, A., & Spodzieja, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02037 · Cited by 4
Zhang, Y., Zhao, Z., Fu, W., & Ding, S. (2023) · Helicobacter · doi:10.1111/hel.12999 · Cited by 4
Microevolutionary processes analysis in the Lithuanian genome
Pranckėnienė, L., Urnikytė, A., & Kučinskas, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-39249-5 · Cited by 4
Liu, Y., Wang, L., Li, Y., Zhong, C., Wang, X., Wang, X., Xia, Z., Liao, J., Huang, C., Mao, C., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00959-1 · Cited by 4
Wang, L., Zheng, Z., Zheng, J., Zhang, G., & Wang, Z. (2024) · Cancer Management and Research · doi:10.2147/cmar.s463694 · Cited by 4
Inhibiting inhibitory pathways in human γδ T cells
Lopez, R. D. (2013) · Blood · doi:10.1182/blood-2013-06-506584 · Cited by 4
“BTLA is a more recently described inhibitory receptor that shares both structural and functional similarities with PD-1 and cytotoxic T lymphocyte–associated antigen 4 (CTLA-4).(2) Although the function of BTLA as an inhibitory receptor on conventional ab T cells is well established,(9)”
BackgroundJavan, M., Rahimpour, A., & Moazzeni, S. M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107966 · Cited by 4
Cbl-b inhibited CD4+ T cell activation by regulating the expression of miR-99a/miR-125b
Wu, M., Gao, X., Tang, Y., Wu, W., Zhou, J., Shao, Y., Hao, C., Yang, Y., & Zhang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109677 · Cited by 5
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Self-citationPhosphorylation: A Fast Switch For Checkpoint Signaling
Wang, Y., Wang, P., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_15 · Cited by 6
Soldi, L. R., Silva, V. L. C., Rabelo, D. H., Uehara, I. A., & Silva, M. J. B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04575-8 · Cited by 6
Dendritic Cells and Their Role in Linking Innate and Adaptive Immune Responses
Lipscomb, M. F., Wilder, J. A., & Masten, B. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-33785-2_2 · Cited by 4
B and T lymphocyte attenuator expression in mature B cell lymphomas
Trougouboff, P., & Shefer, H. K. (2012) · Journal of Hematopathology · doi:10.1007/s12308-012-0173-5 · Cited by 4
“BTLA expression was not detected in non-immune cells [1, 5, 6].”
BackgroundDynamic Regulation of T Cell Activation by Coupled Feedforward Loops
Buri, G., Zelleke, G. M., & Ndifon, W. O. (2021) · Mathematics of planet earth · doi:10.1007/978-3-030-50826-5_9 · Cited by 5
Pardoll, D. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00006-0 · Cited by 5
Expression levels of key immune indicators and immune checkpoints in manganese-exposed rats
Qi, Y., Si, H., Jin, X., Guo, Y., Xia, J., He, J., Deng, X., Deng, M., Yao, W., & Hao, C. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116029 · Cited by 3
Clinical significance of BTLA gene expression and rs1982809 polymorphism in pan-cancer
Gao, X., Gao, Y., Pan, S., & Yang, L. (2023) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2023.2296615 · Cited by 3
“[6,19,20] The tyrosine-containing motif of sequence YDND interacts with growth factor receptor binding 2 before engaging with the p85 subunit of PI3K, which is associated with BTLA's pro-survival effect.”
Ideal donors, imperfect results in sickle cell disease
Thompson, A. A. (2013) · Blood · doi:10.1182/blood-2013-06-507368 · Cited by 3
Bao, Y., Mo, J., Wu, J., & Chenxi, C. (2019) · Chinese Medical Sciences Journal · doi:10.24920/003498 · Cited by 4
del Rio, M., de Juan, C. Y.-D., Roncador, G., Caleiras, E. J., Estebán, R. Á., Pérez‐Simón, J. A., & Rodríguez-Barbosa, J.-I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113858 · Cited by 3
“To gain insight into the role of HVEM/BTLA/CD160/LIGHT pathway in the net balance of coinhibitory and costimulatory signals provided by tumor cells to T cells and NK cells, HVEM gene was mutated in A20 leukemia cells and the anti-tumor response was evaluated in the context of hybrid resistance and parental tumor impla…”
BackgroundResultInfluentialRios, W. M., & de Molfetta, J. B. (2015) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000302 · Cited by 3
“BTLA-deficient T cells display increased proliferation in specific T lymphocytes stimulated by antigen-DCs [52].”
BackgroundCell Activation and Signaling in Lymphocytes
Carmo, A. M., & Henriques, S. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-44436-5_5 · Cited by 3
Takahashi, H., Okayama, N., Yamaguchi, N., Nomura, M., Miyahara, Y., Mahbub, M., Hase, R., Morishima, Y., Suehiro, Y., Yamasaki, T., et al. (2021) · Cancers · doi:10.3390/cancers13112752 · Cited by 3
“Linkage disequilibrium (LD) between two SNPs in a single gene, namely, rs9288952 and rs76844316 in BTLA, was similar among the recipients, donors, and JPT104 (Table S5).”
BackgroundInfluentialGudi, R. R., Perez, N., Karumuthil‐Melethil, S., Li, G., & Vasu, C. (2022) · Immunology · doi:10.1111/imm.13476 · Cited by 3
“CTLA4, programmed cell death-1 (PD1) and B- and T-lymphocyte attenuator (BTLA) are the major checkpoint receptors of CD28 family expressed on T cells [7,8].”
BackgroundBasics of immunooncology and immunotherapy in oncology
Логинова, Е. Н., Lyalyukova, E. A., Nadey, E. V., & Semenova, E. V. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-129-139 · Cited by 4
Haq, I. U., Rahim, K., Rafiq, M., Asif, T., Alvi, S., & Yaseen, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95047-3.00020-4 · Cited by 7
PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer
Li, D., Ma, L., Bao, J., Cao, L., & Min, W. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s383481 · Cited by 4
“Immunosuppression mediated by the PD-L1/PD-1 signaling pathway has been shown to increase the apoptosis of antigen-specific human T cell clones in tumor tissues and cells and inhibit the activation of CD4+/CD8+T cells in vitro, thereby enhancing the immune tolerance of tumor cells and promoting immune escape.(20,21) A…”
BackgroundAldahlawi, A., Basingab, F. S., Alrahimi, J., Zaher, K. A., Pushparaj, P. N., Hassan, M., & Al‐Sakkaf, K. (2023) · Biomedical Reports · doi:10.3892/br.2023.1638 · Cited by 4
“T)‑cell suppression has been shown to be mediated by aberrant expression of BTLA and HVEM (7), which has been linked to leukemia (9) and B‑cell malignancy (10).”
Costimulatory receptors in the channel catfish: CD28 family members and their ligands
Quiniou, S. M. A., Bengtén, E., & Boudinot, P. (2024) · Immunogenetics · doi:10.1007/s00251-023-01327-3 · Cited by 3
“BTLA regulation of T cell activation is important to maintain tolerance as demonstrated by the high frequency of autoimmune diseases in btla KO mice (Watanabe et al. 2003).”
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.